| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Toshiaki Okamoto, Masahiko Koda, Kennichi Miyoshi, Takumi Onoyama, Manabu Kishina, Tomomitsu Matono, Takaaki Sugihara, Keiko Hosho, Junichi Okano, Hajime Isomoto and Yoshikazu Murawaki |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Masahiko Koda, MD, PhD, Associate Professor, Second Department of Internal Medicine, Tottori University, Nishi-cho 36-1, Yonago, Tottori 683-8504,
Japan. masakoda@grape.med.tottori-u.ac.jp |
| Key Words |
Endothelin; Ambrisentan; Steatohepatitis; Hepatic stellate cell; Hepatic fibrosis; Oxidative stress; Hepatic hydroxyproline |
| Core Tip |
Endothelin (ET) can activate hepatic stellate cells, leading to the progression of hepatic fibrosis. Fur-thermore, ET-1 may increase the inflow of free fatty acids from the fat tissue into the liver and exacerbate hepatic steatosis. Therefore, ET-1 antagonism may be a novel target for steatohepatitis. The present study showed that ambrisentan, an ET type A receptor antagonist, attenuated hepatic fibrosis by inhibiting hepatic stellate cell activation, without affecting hepatic steatosis, in a non-alcoholic steatohepatitis mouse model.
|
| Publish Date |
2016-08-03 08:12 |
| Citation |
Okamoto T, Koda M, Miyoshi K, Onoyama T, Kishina M, Matono T, Sugihara T, Hosho K, Okano J, Isomoto H, Murawaki Y. Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model. World J Hepatol 2016; 8(22): 933-941 |
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i22/933.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i22.933 |
